Materialise acquires FEops to expand cardiological capabilities of its Mimics Planner software
Implementation of FEops solutions to enhance anatomical planning and AI-based simulation
Materialise has announced the acquisition of Belgian company FEops, which develops AI-driven simulation technology to improve the efficiency of procedures and clinical outcomes in structural heart interventions. The acquisition will allow Materialise to expand its cardiovascular solutions with predictive simulation capabilities, contributing to more personalized treatment of patients with heart diseases.
FEops combines predictive simulation technology with AI, enabling clinicians to more accurately predict how transcatheter structural heart devices will interact with a patient's anatomy. Now, it will be integrated with the Mimics Planner software developed by Materialise, which allows the creation of accurate virtual 3D models based on medical imaging data.
The integration of FEops with Mimics Planner will enable a comprehensive solution for 3D anatomical planning and AI-based simulation, allowing clinicians to simulate the interaction between a medical device, such as a heart valve, and a patient’s unique anatomy.
Brigitte de Vet, CEO of Materialise, commented on the acquisition:
By integrating FEops’ advanced predictive simulation technology with our Mimics Planner, we are expanding our cardiovascular solutions to provide clinicians with comprehensive insights into patient anatomy. This integration will not only enhance the accuracy and efficiency of structural heart interventions but also improve clinical outcomes and patient safety.
Materialise is advancing mass personalization in healthcare by facilitating the creation of image-based virtual 3D models for pre-procedural planning, increasing the precision and success of complex procedures. These models enable the creation of personalized medical devices, guides, and implants tailored to the precise anatomical specifications of individual patients, which enhances the effectiveness of treatment and makes personalized healthcare more efficient and accessible to a larger number of patients.
Source: Materialise press release